



CORONA Remedies Limited

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059, Gujarat, India.

Tele.: +079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

May 11, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai - 400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results of the Company for Q4FY26 and year ended March 31, 2026.

The press release is also being made available on the website of the Company at www.coronaremedies.com

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

PRESS RELEASE

CORONA Remedies reports strong Revenue growth of 17.3% & PAT¹ growth of 33.4% in FY 2026 on a Y-o-Y basis; driven by Strong Brand Building initiatives & Execution Excellence

Ahmedabad | May 11, 2026

CORONA Remedies Limited, leading India-focused branded pharmaceutical company, announced its audited financial results for Q4FY26 & FY26, showcasing robust financial performance driven by strong brand-building initiatives, portfolio expansion, and operational efficiencies.

◇ Key Highlights

- **Revenue Growth:** Achieved **20.2% YoY growth in Q4FY26 and 17.3% growth in FY26**, driven by focused brand-building initiatives.
- **Margin growth:** Q4FY26 & FY26 PAT¹ grew by **43.7% & 33.4%** respectively supported by **operating leverage and cost optimization**.
- **Strategic Acquisition:** Acquired **WOKADINE** marking entry into the **₹648 Cr Povidone Iodine market**. Acquisition has been funded through internal accruals.
- **Portfolio Expansion:** Relaunched key brands—Fostine R and Menodac under Women’s Health Therapeutics, and Noklot in the Cardiovascular segment—thereby expanding the addressable market.
- **Infertility Segment Focus:** Established a dedicated team to capture high-growth specialty segment.
- **Brand Strength:** Achieved milestone of **2 brands crossing ₹100 Cr MAT revenue (March 26)**, reflecting strong brand equity.
- **Industry Ranking:** Improved market position to **27th rank in India**; consistently moving **5 spots ahead in last 3 years**.

◇ Financial Performance Snapshot

Particulars (₹ Cr)	Q4FY26	Q4FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenue from Operations	353.1	293.7	20.2%	1,403.2	1,196.4	17.3%
EBITDA	62.0	54.2	14.4%	293.4	240.0	22.3%
EBITDA Margin	17.6%	18.5%	(89) bps	20.9%	20.1%	85 bps
Profit After Tax ¹	45.3	31.5	43.7%	199.4	149.4	33.4%
PAT Margin ¹	12.8%	10.7%	210 bps	14.2%	12.5%	172 bps

¹Includes one-time statutory impact of New Labor Code ₹19.1 Crores (Post Tax ₹14.3 Crores) in FY26

◇ Management Commentary

Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said:

'FY26 has been a strong year for CORONA Remedies, marked by consistent revenue growth and enhanced operational efficiency. Our strategic focus on **brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions** continues to strengthen our competitive positioning.

With strategic initiatives like acquisition of WOKADINE and global accreditations, we are well-positioned to drive sustainable growth in years to come.'

◇ Business Highlights

Strategic Acquisitions & Portfolio Expansion

- Entry into **Povidone Iodine market** through WOKADINE acquisition.
- Leveraging **Bayer-Zyodus portfolio** through relaunch of key brands.

Market Positioning & Growth

- Improved **industry ranking to 27th** from 32nd in last three years.
- Chronic therapies continued to perform well, contributing **~72.3% & 71.9%** of total Revenue in Q4FY26 and FY26 respectively.

Manufacturing and R&D Excellence

- **EAEU-GMP certification** enables entry into **Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan** markets.

About CORONA Remedies Limited

Founded in 2004, CORONA Remedies Limited is a leading India-focused pharmaceutical company engaged in developing, manufacturing, and marketing products across key therapeutic areas including women's healthcare, cardio-diabetes, pain management, and urology. The company operates WHO-GMP/EU GMP-certified manufacturing facilities and maintains strong innovation capabilities through DSIR-approved R&D centers.

Safe Harbor

This document may contain forward-looking statements about CORONA Remedies Limited which are based on the beliefs, opinions, and expectations of the company's management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

For further information please contact

Company	Investor Relations Advisors
CORONA Remedies Limited CIN No: L24231GJ2004PLC044656 Chetna Dharajiya – Company Secretary & Compliance Officer investor@coronaremedies.com	Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Sagar Shroff / Tanay Shah Email id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899